San Carlos, Calif. – October 12, 2026 -- Noah Medical's Galaxy robotic bronchoscopy platform delivered a 96.7% strict diagnostic yield in a 31-patient multi-center study, and an 89% yield with a cost-benefit ratio above 1 in a separate community hospital series, according to two data sets presented at the CHEST 2025 Annual Meeting in Chicago.
MATCH 2 study reports 100% procedural success across 31 patients
The prospective multi-center MATCH 2 study was led by Dr. Amit "Bobby" Mahajan of Inova Fairfax Medical Center in Virginia and Dr. Krish Bhadra of CHI Memorial in Tennessee. Investigators evaluated the Galaxy System's digital tomosynthesis and augmented fluoroscopy algorithms for real-time lesion localization in patients with peripheral pulmonary nodules.
Results across the 31 patients:
- 100% procedural success, with the biopsy tool deployed within the target lesion.
- 97% tool-in-lesion confirmation using TiLT+ imaging.
- 96.7% concordance between TiLT+ images and cone-beam CT (CBCT) confirmation.
- 96.7% overall diagnostic yield under strict definitions.
Mahajan said the data show TiLT+ imaging gives intraprocedural guidance comparable to CBCT, and that the platform could extend advanced robotic bronchoscopy to centers without CBCT capability.
Community hospital study of 70 cases finds 89% strict yield at index procedure
The second study, "Beyond the Scope," reviewed 70 consecutive Galaxy System cases performed over 18 months in a community hospital lung nodule program. Localization in two or more augmented-fluoroscopy planes (p < 0.001) and direct tool adjustments with peripheral lesion visualization (p = 0.01) were the key predictors of diagnostic yield.
Cost-benefit ratios of 1.5 and 1.1 clear viability threshold
Procedures performed in an endoscopy suite returned a cost-benefit ratio (CBR) of 1.5, while those in the operating room returned 1.1. The study treated a CBR above 1 as financially viable, so both settings cleared the threshold, with the endoscopy suite showing the wider margin.
Principal investigator Dr. Roshen Mathew said community centers are critical access points for early lung cancer diagnosis and that robotic bronchoscopy with integrated augmented fluoroscopy can be clinically and economically viable there.
Noah Medical cites FDA clearance from March 2023 as it expands globally
Noah Medical describes the Galaxy System as the first robotic-assisted bronchoscopy platform combining embedded imaging with advanced visualization, a single-use scope and an efficient workflow. The system received FDA clearance in March 2023 and is the company's first commercial robotic system. Founder and CEO Jian Zhang said the company continues to expand its commercial footprint globally.